Prior to publication, the information contained within this announcement was deemed by the Company to constitute inside information as stipulated under the Market Abuse Regulations (EU) No. 596/2014 ("MAR") (which forms part of Domestic UK Law pursuant to the European Union (Withdrawal) Act 2018). With the publication of this announcement, this information is now considered to be in the public domain.

Feedback plc

Bleepa^Ⓡ awarded contract at Royal Berkshire NHS Foundation Trust

·      First direct commercial contract for Bleepa from the NHSx Clinical Communications Framework

·      Bleepa to be rolled-out in targeted clinical settings at the Royal Berkshire NHS Foundation Trust as part of a one year £84,000 contract

·      New Bleepa features to be released for the Trust: Virtual Multi-Disciplinary Meetings, referral pathways and Photocapture to securely share medical photographs

London, 24 March 2021: Feedback plc (AIM: FDBK, "Feedback" or the "Company"), the specialist medical imaging technology company, today announces it has been awarded a one year contract with a value of £84,000 with the Royal Berkshire NHS Foundation Trust ("the Trust") for Bleepa, its flagship clinical communications platform, across a number of targeted clinical settings. The contract funding has been drawn down from the NHSx National Clinical Communication Tool Framework.

The Royal Berkshire NHS Foundation Trust, which operates The Royal Berkshire Hospital in Reading, is a leading healthcare provider with an established track record of digital innovation. The Trust is keen to evaluate Bleepa as part of its wider communication strategy and is a frontrunner in recognising the need to transition away from unregulated platforms such as WhatsApp for clinical communication.

The Trust will have access to the latest features on the Bleepa platform:

·      Feedback will work with the Trust to enhance Virtual Multi-Disciplinary Meetings module (MDTs). MDTs are essential to delivering streamlined patient care. However, the gathering of specialist clinicians from different clinical settings to assess patient cases is time consuming, costly and inefficient, with the logistical complexities accentuated during the COVID-19 pandemic. Bleepa supports a new way of running MDTs asynchronously and the Bleepa image viewer function will enable each clinical participant in the MDT to see imaging in the correct clinical quality, something that cannot be achieved through screenshares on a video call currently, ensuring regulatory compliance.

·      Photocapture has been in development by the Company for the last three months and will form part of a planned product release, version 1.3. The photocapture module enables clinicians to acquire clinical images of patients, such as medical photographs of skin lesions or wounds, where no patient data resides on the device used. These photographs will be added to the Bleepa patient file which can then be shared with clinical colleagues for discussion and become part of the patient record. The Trust will provide a clinical evaluation of the photocapture module which will form part of the CE marking process for the new feature.

·      Feedback will also work with the Trust to evaluate the referral module of the product, linking it to the existing workflow for clinical, intra-Trust referral pathways embedded in the Trust's Electronic Patient Record. As Bleepa referral management aligns with clinical best practice and supports standardisation along the patient pathway, it has the capability to improve clinical communication.

The photocapture module will enable Bleepa to be used for a wider range of services outside of this contract such as dermatology services, community nursing and diabetes wound management, allowing Bleepa to reach a wider clinical audience outside of the secondary care setting, in a zero footprint way. 

Investor Presentation

The Company is pleased to announce that Tom Oakley, CEO of Feedback, will provide a live presentation relating to today's announcement via the Investor Meet Company platform on Tuesday 30 March 2021 at 12:00pm BST.

The presentation is open to all existing and potential shareholders. Questions can be submitted pre-event via the Investor Meet Company dashboard up until 9.00am BST the day before the meeting or at any time during the live presentation.

Investors can sign up to Investor Meet Company for free and add to meet Feedback plc via:

https://www.investormeetcompany.com/feedback-plc/register-investor

Investors who already follow the Company on the Investor Meet Company platform will be automatically invited.

Dr Tom Oakley, CEO of Feedback, commented:

"We are delighted to be working with a Trust that has clearly demonstrated a commitment to driving innovation for their clinicians by providing a platform for secure digital medical communications. This contract is recognition of the huge work that has gone into making Bleepa the most reputable tool on the market and clearly demonstrates product market fit. As we have seen in previous clinical settings, Bleepa has the ability to streamline the patient pathway and save clinicians time, no matter their location, and we look forward to building a strong and successful relationship with the Royal Berkshire NHS Foundation Trust."

Nigel Uwins, Assistant Director IT Support and Architecture at the Royal Berkshire NHS Foundation Trust, commented:

"The Trust is excited to work with Feedback to implement and utilise the capabilities of the Bleepa platform in a number of areas. We were successful in obtaining NHSE funding for this work and Bleepa were selected using the Clinical Communications Framework. We have found Feedback very co-operative and are looking forward to a successful partnership with them in the coming months."

-Ends-

Enquiries:

Notes to editors

Feedback plc (AIM: FDBK) is a medical imaging technology business. Its core product, Bleepa, is a revolutionary medical imaging communications app, providing an easy-to-use, high quality tool to enable remote and secure communications between front-line clinicians and teams. Importantly, it is the only CE marked medical imaging communications platform on the NHSx clinical communications tools framework. Bleepa has unparalleled functionality for everyday practice and can be accessed from any internet-connected device, enabling control of patient cases when on the go.

Its highly scalable Software as a Service ("SaaS") based revenue model will provide increasing levels of visibility as the Company grows its customer base. With a growing distribution base and technology in place, the focus is on leveraging key relationships in order to drive sales both in the UK and internationally to all forms of care facilitators. As a fully certified medical device, Bleepa aims to disrupt the medical imaging communications market and, importantly, increase the accuracy and speed of diagnosis.